COSCIA, Marta
 Distribuzione geografica
Continente #
NA - Nord America 9.071
EU - Europa 6.111
AS - Asia 3.634
AF - Africa 169
SA - Sud America 43
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 28
Totale 19.088
Nazione #
US - Stati Uniti d'America 8.968
CN - Cina 1.983
IT - Italia 1.490
SG - Singapore 906
DE - Germania 786
IE - Irlanda 753
SE - Svezia 718
UA - Ucraina 456
AT - Austria 454
FR - Francia 384
FI - Finlandia 339
GB - Regno Unito 160
KR - Corea 160
IN - India 134
VN - Vietnam 126
SN - Senegal 124
PL - Polonia 123
CA - Canada 95
JP - Giappone 73
HK - Hong Kong 63
DK - Danimarca 57
NL - Olanda 56
BE - Belgio 51
ES - Italia 50
ID - Indonesia 48
GR - Grecia 44
RU - Federazione Russa 41
BY - Bielorussia 40
CH - Svizzera 31
AU - Australia 30
EU - Europa 28
TW - Taiwan 28
BR - Brasile 25
IR - Iran 25
CZ - Repubblica Ceca 20
UZ - Uzbekistan 18
RO - Romania 17
EG - Egitto 14
TR - Turchia 13
TH - Thailandia 12
ZA - Sudafrica 11
AR - Argentina 8
LU - Lussemburgo 7
PH - Filippine 7
PT - Portogallo 7
SA - Arabia Saudita 7
HU - Ungheria 6
IL - Israele 6
MO - Macao, regione amministrativa speciale della Cina 6
MX - Messico 6
PK - Pakistan 6
NO - Norvegia 5
CL - Cile 4
NG - Nigeria 4
AM - Armenia 3
CI - Costa d'Avorio 3
DZ - Algeria 3
IQ - Iraq 3
LT - Lituania 3
MK - Macedonia 3
RS - Serbia 3
UY - Uruguay 3
LK - Sri Lanka 2
MA - Marocco 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
TG - Togo 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CO - Colombia 1
EC - Ecuador 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
KH - Cambogia 1
MD - Moldavia 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
Totale 19.088
Città #
Chandler 1.339
Beijing 1.081
Dublin 751
Santa Clara 741
Singapore 681
Vienna 448
Ashburn 429
Ann Arbor 393
Jacksonville 331
Torino 329
Houston 325
Nyköping 300
Fairfield 297
Medford 274
Dearborn 271
Wilmington 235
Princeton 232
Columbus 219
Villeurbanne 217
San Mateo 169
Woodbridge 143
Turin 142
Munich 140
Fremont 135
Redwood City 115
Seattle 112
Guangzhou 106
Helsinki 103
Warsaw 101
Milan 99
Cambridge 89
Dong Ket 83
New York 77
Shanghai 63
Boston 59
Nanjing 57
Toronto 57
Hangzhou 50
Hefei 50
Washington 49
Jakarta 47
Centro 45
Florence 43
Pisa 43
Brussels 42
Boardman 41
Norwalk 41
Chengdu 37
Düsseldorf 37
Rome 37
Hong Kong 27
Los Angeles 25
Nürnberg 25
San Diego 25
Seoul 25
Chennai 24
Wuhan 22
Hebei 21
Kunming 19
Taipei 19
Falls Church 18
Pune 18
Shenyang 18
Mountain View 17
Ottawa 17
San Jose 17
Tokyo 16
Xian 16
Central District 15
Guiyang 15
Hyderabad 15
Nanchang 15
Phoenix 15
Zhengzhou 15
Jinan 14
Piemonte 14
Barcelona 13
Changsha 13
Nuremberg 13
São Paulo 12
Tianjin 12
Bologna 11
Chicago 11
Chieri 11
Lappeenranta 11
Linden 11
Des Moines 10
Jaipur 10
Paris 10
Philadelphia 10
Upper Marlboro 10
Falkenstein 9
Genova 9
Provo 9
Rotterdam 9
Verona 9
Changchun 8
Dallas 8
Fuzhou 8
Madrid 8
Totale 12.037
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 750
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. 507
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22 331
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 292
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 292
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 288
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 205
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 202
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 185
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 176
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 172
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 164
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 163
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 149
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 148
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 145
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 141
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 139
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 136
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 135
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 133
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 133
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 133
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 133
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 130
Effective anti-tumor immunomodulatory properties of zoledronic acid 127
AISF position paper on HCV in immunocompromised patients 127
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 127
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 125
THE PD-1/PD-L1 AXIS CONTRIBUTES TO T CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA 119
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 119
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 119
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence 119
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 117
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 116
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 115
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 115
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 114
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 113
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 112
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 111
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 111
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 110
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 110
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 109
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 109
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 108
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 108
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 107
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 107
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 105
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 105
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 105
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 105
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 105
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 103
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 103
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 103
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 103
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 102
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 101
Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients 101
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 100
Real life use of bendamustine in elderly patients with lymphoid neoplasia 100
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 99
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 98
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 98
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 96
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 95
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 95
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 95
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 95
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 94
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 93
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 92
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 92
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 92
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS 92
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 92
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 91
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 91
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 89
Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions 89
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 89
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 89
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 88
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 88
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. 88
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 88
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma 87
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma 87
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 87
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. 86
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 86
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide 86
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22 85
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 85
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID 84
Totale 13.069
Categoria #
all - tutte 63.183
article - articoli 0
book - libri 0
conference - conferenze 32.078
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.261


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.044 0 0 0 0 0 0 260 132 123 213 165 151
2020/20212.730 232 188 115 162 365 135 179 174 288 174 397 321
2021/20223.148 157 90 154 269 178 149 404 161 102 304 683 497
2022/20233.721 420 362 98 384 277 902 272 251 398 119 143 95
2023/20241.734 187 306 118 71 110 290 32 150 19 95 118 238
2024/20252.739 40 250 192 514 1.211 330 202 0 0 0 0 0
Totale 19.796